ArticleCureus2026
Survival Trends in Metastatic Renal Cell Carcinoma Across Therapeutic Eras and Histologic Subtypes.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Immune checkpoint inhibitors have transformed the treatment of metastatic renal cell carcinoma (RCC). Whether these advances translated into population-level survival improvements across histologic subtypes remains uncertain. Materials and methods We performed a retrospective cohort study using the Surveillance, Epidemiology, and End Results (SEER) database (2006-2022). Patients older than 20 years with distant-stage RCC were categorized into a targeted therapy era (2006-2015) and an immunotherapy era (2016-2022). Overall survival (OS) and cancer-specific survival (CSS) were evaluated using Kaplan-Meier analysis, restricted mean survival time (RMST) analysis (τ=36 months), and multivariable Cox models adjusting for demographic and clinical variables. The interaction between treatment era and histologic subtype was assessed. Sensitivity analyses were restricted to clear cell RCC. Results Among 7,356 patients, 5,814 (79.0%) were diagnosed during the targeted therapy era and 1,542 (21.0%) during the immunotherapy era, median OS improved from 13 months (95% CI: 13-14) to 17 months (95% CI: 15-19), and median CSS improved from 14 months (95% CI: 14-15) to 19 months (95% CI: 17-21) (both p<0.001). Diagnosis during the immunotherapy era was associated with improved OS (HR: 0.80, 95% CI: 0.76-0.86) and CSS (HR: 0.77, 95% CI: 0.73-0.83). At 36 months, RMST demonstrated absolute gains of 1.82 months for OS and 1.99 months for CSS (both p<0.001). Survival benefit was attenuated in papillary and chromophobe RCC but remained consistent in clear cell RCC. Conclusions Diagnosis during the immunotherapy era was associated with survival improvement in metastatic RCC, predominantly driven by clear cell histology, reinforcing the need for subtype-specific approaches in non-clear cell RCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.